

Remarks

Accompanying this amendment are a Request for Continued Examination (RCE) and a Supplemental Information Disclosure Statement. Upon entry of this amendment, Claims 28 and 33-34 will be pending. Claim 28, which was allowed in the Notice of Allowance mailed July 25, 2007, is directed to the treatment of helminth infections with a human IL-174 protein consisting of SEQ ID NO:2. After allowance, Applicants noticed that SEQ ID NO:2 includes the predicted signal peptide sequence; see, e.g., the second set of features <221> and <222> of SEQ ID NO:1 (lines 37-38 on page 1 of the Sequence Submission in the application as filed), as well as the negative numbering of the first 16 amino acids shown in SEQ ID NOs:1 and 2. Thus, Applicants are submitting for examination new Claims 33 and 34, which do not require the presence of the signal peptide sequence in the IL-174 protein used in the claimed treatment method. No new matter is added by this amendment to the claims, and its entry is respectfully requested.

Applicants also have become aware of art not previously cited in this application and have listed this art on the accompanying Supplemental Information Disclosure Statement. Applicants request that the Examiner consider this additional art with respect to both Claims 28 and 33.

If the Examiner believes any new issues are generated by this amendment and RCE, the Examiner is invited to contact Applicants undersigned attorney at the number set forth below.

Respectfully submitted,

Date: 10/24/07

Melodie W. Henderson
Melodie W. Henderson
Reg. No. 37,848

Schering-Plough Corporation
Patent Department
Mail Stop K-6-1, 1990
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530

Phone: (908) 298-7482
Fax: (908) 298-5388